Novavax Inc vs Wayfair Inc — how do they compare? Novavax Inc trades at $8.08 (market cap $1.30B), while Wayfair Inc trades at $84.81 (market cap $11.58B). The key difference: Wayfair Inc is far larger — about 8.9× Novavax Inc's market cap. Which is the better fit depends on your goals.
| NVAX | W | |
|---|---|---|
Market Cap | $1.30B | $11.58B |
Sector | Health | Consumer Cyclical |
52-Week High | $11.19 | $119.05 |
52-Week Low | $6.22 | $56.42 |
Enterprise Value | $800.50M | $14.16B |
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →